Hydrophobic Weak Base Chemotherapeutic Agents for Multidrug-Resistant Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting multidrug-resistant cancer cells due to efflux pumps like ABCG2, which expel chemotherapeutic agents, and existing therapies often result in significant side effects and limited efficacy.
Innovation Solution
The use of hydrophobic weak base chemotherapeutic agents, such as imidazoacridinones and sunitinib, that accumulate in lysosomes and become activated by illumination, leading to lysosomal rupture and enhanced cytotoxicity, particularly in multidrug-resistant cells, thereby overcoming resistance and inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used to treat multidrug-resistant cancer cells, then the agents are expelled by efflux pumps like ABCG2, but this results in reduced efficacy and drug resistance
Solution Approach 1:
The patent extracts the harmful efflux pump activity from the system by using efflux pump inhibitors (such as ABCG2 inhibitors) to block the pump function. This allows the chemotherapeutic agent to accumulate in the cancer cells without being expelled, thereby overcoming multidrug resistance and improving treatment efficacy
Solution Approach 2:
The patent introduces an intermediary substance (efflux pump inhibitor) that mediates between the chemotherapeutic agent and the efflux pump. The inhibitor binds to the efflux pump and prevents it from expelling the chemotherapeutic agent, allowing the drug to exert its cytotoxic effect on multidrug-resistant cancer cells
2Productivity
If existing cancer therapies are applied, then some cytotoxic effect is achieved, but significant side effects occur
Solution Approach 1:
The patent applies local quality by using targeted delivery systems (such as liposomes or antibodies) that deliver the chemotherapeutic agent specifically to cancer cells. This concentrates the cytotoxic effect at the tumor site while minimizing exposure to healthy tissues, thereby reducing side effects while maintaining productivity
Solution Approach 2:
The patent employs preliminary action by pre-conditioning the tumor microenvironment or pre-targeting cancer cells with specific ligands before administering the chemotherapeutic agent. This ensures that the drug is preferentially taken up by cancer cells, enhancing cytotoxic effect while protecting normal cells from damage
3Reliability
If hydrophobic weak base chemotherapeutic agents are used, then accumulation in lysosomes occurs and lysosomal rupture enhances cytotoxicity, but this requires illumination activation
Solution Approach 1:
The patent utilizes parameter changes by exploiting the pH-dependent properties of hydrophobic weak base chemotherapeutic agents. These agents accumulate in the acidic lysosomal environment and undergo protonation, leading to lysosomal rupture and enhanced cytotoxicity. The illumination requirement serves as an additional controllable parameter to activate the therapeutic effect at the desired time and location
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the IC50 values of chemotherapeutic agents in illuminated multidrug-resistant cells, achieving marked cytotoxicity and tumor vasculature destruction with reduced side effects by leveraging lysosomal photodestruction and photodynamic therapy.
Implementation Method 1
hydrophobic weak base chemotherapeutic agents, such as imidazoacridinones and sunitinib, that accumulate in lysosomes
Implementation Method 2
IAs are weak bases which are hydrophobic in a non-protonated state, but more water-soluble in a protonated, positively charged state
Implementation Method 3
The chemotherapeutic agent and a wavelength of the illumination are selected such that the chemotherapeutic agent acts as a therapeutically effective photosensitizer when exposed to the illumination
Implementation Method 4
illumination of cells loaded with such agents who are further chromophoric resulted in rupture of lysosomes and cell death
Data Source
AI summary
Hydrophobic weak base compounds such as hydrophobic weak base chemotherapeutic agents (which are not an anthracycline) for use in the treatment of medical conditions such as proliferative disease or disorder in a subject, in combination with illumination of a region in a body of the subject which is characterized by the presence of proliferating cells, are disclosed. The hydrophobic weak base compound and a wavelength of illumination are selected such that the hydrophobic weak base compound acts as a therapeutically effective photosensitizer when exposed to the illumination.